Humanized mice (target-specific)

Well-established mouse lines that allow in vivo efficacy and safety assessment of biologics and other compounds.

‍

Applications & Features

Target-specific humanized models provide a robust platform for advancing drug development and therapeutic research across a wide range of biomedical fields, including oncology, immunology, and inflammation.

These models enable predictive and translational preclinical research, supporting diverse applications such as:

Evaluating the efficacy of T-cell engagers (e.g., Pan hCD3 model), biologics, and small molecules (e.g., hTFRC)
Investigating immune checkpoints and assessing them as potential drug targets (e.g., hPD-1 and hVISTA)
Testing antibody-dependent therapies (e.g., hFcgR)
Conducting pharmacokinetic (PK) analysis (e.g., HSA/hFcRn)

Immunocompetent and free from murine target gene expression, the models exhibit physiological, human-like target expression while preserving critical cell/cell and ligand/target interactions. These features make them an invaluable resource for syngeneic studies.

Related resources and publications

CD137

pulmonary embolism (PE)

osteomyelitis

hyperalgesia

PET imaging

intrauterine growth deficiency

Myopia

ossification

cGAS

cGAS-STING pathway

TFRC

FX-deficiency

muscle-eye-brain disease (MEB)

Tumor microenvironment

primary immunodeficiency (PID)

Oncology

Pharmacology

Neuroscience

Metabolism

Inflammation

Immunology

Respiration

Cardiovascular

Ophthalmology

Nephrology

Musculoskeletal

Hematology

Epigenetics

Development

Endocrinology

Dermatology

Humanization

Rosa26

TET system

Hprt

CreERt2

FLEx

innate immunity

Transgenesis

infection

vision

immune response

dementia

central nervous system (CNS)

taste

transplantation

autoimmunity

thermoregulation

sugar homeostasis

stress

skelet

pulmonary research

nutrition

pain research

muscle research

locomotion

memory

hearing

fat homeostatsis

tissue research

epigentic modification

drugs

cancer research

cell research

behavior

aging

stem cell research

reproductive research

lymphatic system

learning

heart research

gut research

genetic research

exercise

bone research

embryonic development

dental research

blood research

von Willebrand disease (VWD)

X-linked adrenoleukodystrophy (X-ADL)

Vanishing White Matter (VWM) disease

type 2 diabetes (T2D)

ulcerative colitis (UC)

type 1 diabetes (T1D)

thrombosis

thrombocytopenia

systemic lupus erythematosus (SLE)

tauopathy

stenosis

steatohepatitis

spinocerebellar ataxia type 2 (SCA2)

small cell lung cancer

SHORT syndrome

sepsis

schizophrenia

Senescence-associated secretory phenotype (SASP)

seizure

sarcoidosis

rhesus-deficiency syndrome

retinopathy

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

(Sensei) Conditionally active CD28xVISTA bispecific antibodies induce myeloid-driven tumor-specific T-cell co-stimulation for improved cancer immunotherapy

CD28xVISTA bispecific antibodies in immunotherapy

(Bonum) A Novel Method for Generating Regulated Cytokine Therapeutics: Safety and Activity of a Conditionally Active cLAG3-IL2 Capable of Delivering IL-2 to LAG-3+ Cells While Remaining Inert on LAG-3- Cells

Safety and activity of a conditionally active cLAG3-IL2

(Cidara) Discovery of a multispecific CD73/PD-1 targeting Drug Fc-Conjugate (DFC), which improves tumor reduction compared to PD-1 monotherapy in a humanized mouse model

Multispecific CD73/PD-1 targeting

Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies

FcγR mouse models for efficacy and PK/PD

CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies

CD28-targeting therapies

Novel TFRC humanized mouse model for drug delivery to the brain

Drug delivery to the brain (TFRC)

Cell-depleting agents assessment in preclinical models

BRGSF-HIS & hFcγR to assess cell depletion

(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

CD3 binding T-cell engagement

(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors

Novel PD-1 targeted IL-2Rβ/γ agonist

(VIB) A Cross-Species Map and Humanized Mouse Model of Fcγ Receptors and FcRn

Humanized Mouse Model of Fcγ Receptors

(Reaction Biology) Humanized PD-1 knock-in mice as a model system for combination therapies with human specific PD-1 therapeutics

hPD-1 to evaluate novel cancer therapies

(Anaveon) ANV600 is a potent, cis-signaling, IL-2Rβ/γ directed IL-2 which efficiently expands intratumoral stem-like CD8 T cells

PD-1 & strong tumor growth inhibition

(Maxivax) Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells drives tumor response and prolongs survival in a colorectal cancer model

CTLA-4 & survival in a colorectal cancer model

(Arcus) AB598, a Therapeutic Anti-Human CD39 Antibody, Binds and Inhibits CD39 Enzymatic Activity In Vivo to Promote Anti-Tumor Immunity

Anti hCD39 to promote anti-tumor immunity

CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

CD3 and BRGSF-HIS to assess IrAEs

Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

BRGSF-HIS & hVISTA for immunotherapies

(Sensei) SNS-101, a monoclonal antibody that is highly selective for VISTA in the tumor microenvironment, demonstrates favorable pharmacokinetic and cytokine release characteristics and potentiates anti-PD-1 responsiveness

VISTA in the tumor microenvironment

(Curadev) Intravenous administration of the small molecule STING agonist CRD5500 elicits potent anti-tumor immune responses in cold tumors

hSTING & anti-tumor response in cold tumors

Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

BRGSF-HIS & CD3ε in CRS

(Kineta) A Fully Human anti-VISTA Antibody as a Promising Therapy Against Poorly Immunogenic Tumors

anti-hVISTA against poorly immunogenic tumors

(Charles River) Enhanced anti-tumor lymphocyte function and frequencies measured by multichromatic flow cytometry in human CTLA-4 knock-in mice in a colorectal carcinoma model after treatment with ipilimumab

hCTLA-4 mice as a colorectal carcinoma model

(Charles River) Validation of humanized PD-1 knock-in mice as an emerging model to evaluate human specific PD-1 therapeutics

hPD-1 mice as a model to evaluate human specific PD-1 therapeutics

The ABC transporter A7 modulates neuroinflammation via NLRP3 inflammasome in Alzheimer’s disease mice

Alzheimers Res Ther

NI-3201 Is a Bispecific Antibody Mediating PD-L1-Dependent CD28 Co-stimulation on T Cells for Enhanced Tumor Control

Cancer Immunol Res

In-depth cross-validation of human and mouse CD4-specific minibodies for noninvasive PET imaging of CD4+ cells and response prediction to cancer immunotherapy

Theranostics

Highlighted article

read the comment

Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with 89Zr-labelled CI-8993

Eur J Nucl Med Mol Imaging

Highlighted article

read the comment

Agonistic anti-DCIR antibody inhibits ITAM-mediated inflammatory signaling and promotes immune resolution

JCI Insight

Differential effects of FcRn antagonists on the subcellular trafficking of FcRn and albumin

JCI Insight

HPN328, a Trispecific T Cell-activating Protein Construct Targeting DLL3-Expressing Solid Tumors

Mol Cancer Ther

Highlighted article

read the comment

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

Nat Commun

Highlighted article

read the comment

Common single-base insertions in the VNTR of the carboxyl ester lipase (CEL) gene are benign and also likely to arise somatically in the exocrine pancreas

Hum Mol Genet

Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases

Front Immunol

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

Front Immunol

Highlighted article

read the comment

Rational design of a genomically humanized mouse model for dominantly inherited hearing loss, DFNA9

Hear Res

Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells

Front Immunol

Highlighted article

read the comment

Mistranslation-associated perturbations of proteostasis do not promote accumulation of amyloid beta and plaque deposition in aged mouse brain

Cell Mol Life Sci

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Front Immunol

Highlighted article

read the comment

Widespread monoclonal IgE antibody convergence to an immunodominant, pro-anaphylactic Ara h 2 epitope in peanut allergy

J Allergy Clin Immunol

Transgenic expression of the HERV-W envelope protein leads to polarized glial cell populations and a neurodegenerative environment

Proc Natl Acad Sci U S A

SRF617 Is a Potent Inhibitor of CD39 with Immunomodulatory and Antitumor Properties

Immunohorizons

CCX559 is a potent orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

PLoS One

Highlighted article

read the comment

A gain-of-function filamin A mutation in mouse platelets induces thrombus instability

J Thromb Haemost

The genetic risk factor CEL-HYB1 causes proteotoxicity and chronic pancreatitis in mice

Pancreatology

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Acta Biomater

Highlighted article

read the comment

Hyaluronan Synthase 3 is Protective After Cardiac Ischemia-Reperfusion by preserving the T cell Response

Matrix Biol

Single-Domain Antibodies for Targeting, Detection, and In Vivo Imaging of Human CD4+ Cells

Front Immunol

IgG against the membrane-proximal portion of the desmoglein 3 ectodomain induces loss of keratinocyte adhesion, a hallmark in pemphigus vulgaris

J Invest Dermatol

Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells

J Allergy Clin Immunol

Enhanced half-life and antitumor activity of Interleukin-15 through genetic fusion of a serum albumin-specific protein binder

Int J Pharmac

Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment

J Immunother Cancer

Brain-derived neurotrophic factor expression in serotonergic neurons improves stress resilience and promotes adult hippocampal neurogenesis

Prog Neurobiol

Modification of BRCA1-associated breast cancer risk by HMMR overexpression

Nat Commun

An anti-PD-1–GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy

Nat Cancer

Highlighted article

read the comment

A hotspot mutation targeting the R-RAS2 GTPase acts as a potent oncogenic driver in a wide spectrum of tumors

Cell Rep

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

Sci Rep

Highlighted article

read the comment

Overexpression of wild type RRAS2, without oncogenic mutations, drives chronic lymphocytic leukemia

Mol Cancer

TNAP upregulation is a critical factor in Tauopathies and its blockade ameliorates neurotoxicity and increases life-expectancy

Neurobiol Dis

G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes

ACS Pharmacol Transl Sci

Novel humanized mesothelin-expressing genetically engineered mouse models underscore challenges in delivery of complex therapeutics to pancreatic cancers

Mol Cancer Ther

Cardiac investigations in sudden unexpected death in DEPDC5-related epilepsy

Ann Neurol

Caspase-6-cleaved Tau fails to induce Tau hyperphosphorylation and aggregation, neurodegeneration, glial inflammation, and cognitive deficits

Cell Death Dis

Danuglipron (PF-06882961) in type 2 diabetes: a randomized, placebo-controlled, multiple ascending-dose phase 1 trial

Nat Med

Loss of sphingosine kinase 2 enhances Wilm's tumor suppressor gene 1 and nephrin expression in podocytes and protects from streptozotocin-induced podocytopathy and albuminuria in mice.

Matrix Biol

Albumin protects the liver from tumor necrosis factor α-induced immunopathology

FASEB J

In Vivo Half-Life Extension of BMP1/TLL Metalloproteinase Inhibitors Using Small-Molecule Human Serum Albumin Binders

Bioconjug Chem

Gain-of-function factor H–related 5 protein impairs glomerular complement regulation resulting in kidney damage

Proc Natl Acad Sci U S A

Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1 + Activated T Cells

Cancer Discov

Visualization of Mineral-Targeted Alkaline Phosphatase Binding to Sites of Calcification In Vivo

J Bone Miner Res

Biased M1-muscarinic-receptor-mutant mice inform the design of next-generation drugs

Nat Chem Biol

VISTA is an acidic pH-selective ligand for PSGL-1

Nature

Highlighted article

read the comment

VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance

Science

Highlighted article

read the comment

Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy

Cell

Chemogenetics defines receptor-mediated functions of short chain free fatty acids

Nat Chem Biol

The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation

J Immunother Cancer

Engineered botulinum neurotoxin B with improved binding to human receptors has enhanced efficacy in preclinical models

Sci Adv

Molybdenum cofactor deficiency type B knock-in mouse models carrying patient-identical mutations and their rescue by singular AAV injections

Hum Genet

Humanization of the Blood–Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus — Lessons from Three Unsuccessful Approaches

Eur J Microbiol Immunol

Histological and behavioural phenotypes of a novel mutated APP knock-in mouse

J Alzheimers Dis

Renal Mesangial Cells Isolated from Sphingosine Kinase 2 Transgenic Mice Show Reduced Proliferation and are More Sensitive to Stress-Induced Apoptosis

Cell Physiol Biochem

Sphingosine Kinase 2 Modulates Retinal Neovascularization in the Mouse Model of Oxygen-Induced Retinopathy

Invest Ophthalmol Vis Sci

An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes

JCI Insight

Overexpression of tissue-nonspecific alkaline phosphatase (TNAP) in endothelial cells accelerates coronary artery disease in a mouse model of familial hypercholesterolemia.

PLoS One

Hyaluronan synthase 3 promotes plaque inflammation and atheroprogression

Matrix Biol

Paired Siglec receptors generate opposite inflammatory responses to a human‐specific pathogen.

EMBO J

Selective Enhancement of Insulin Sensitivity in the Endothelium In Vivo Reveals a Novel Proatherosclerotic Signalling Loop.

Circ Res

Tauopathy induced by low level expression of a human brain-derived tau fragment in mice is rescued by phenylbutyrate

Brain

C26:0-Carnitine Is a New Biomarker for X-Linked Adrenoleukodystrophy in Mice and Man.

PLoS One

An antibody biosensor establishes the activation of the M1 muscarinic acetylcholine receptor during learning and memory

J Biol Chem

Transgenic Overexpression of Tissue-Nonspecific Alkaline Phosphatase (TNAP) in Vascular Endothelium Results in Generalized Arterial Calcification.

J Am Heart Assoc

Generation of a double transgenic humanised neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs

J Control Release

Deletion of Hyaluronan Synthase 3 Inhibits Neointimal Hyperplasia in Mice.

Arterioscler Thromb Vasc Biol

In vivo structure‐function studies of human hepatic lipase: the catalytic function rescues the lean phenotype of HL‐deficient (hl−/−) mice

Physiol Rep

Human CD68 promoter GFP transgenic mice allow analysis of monocyte to macrophage differentiation in vivo

Blood

Pathophysiological role of vascular smooth muscle alkaline phosphatase in medial artery calcification

J Bone Miner Res

Knock-In of Human BACE1 Cleaves Murine APP and Reiterates Alzheimer-like Phenotypes

J Neurosci

Caspase-6 activity in the CA1 region of the hippocampus induces age-dependent memory impairment

Cell Death Differ

Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent.

Cell Mol Life Sci

The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model

Blood

Novel role of the IGF-1 receptor in endothelial function and repair: studies in endothelium-targeted IGF-1 receptor transgenic mice.

Diabetes

Abnormal Cognition Sleep EEG and Brain Metabolism in a Novel Knock-In Alzheimer Mouse PLB1.

PLoS One

Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.

J Pharmacol Exp Ther

A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

Humanized ICP in immuno-oncology

Part 1: Toward a better effective preclinical model in immuno-oncology

Immuno-oncolology models

A VISTA on naive T cell fate

Humanized ICP mouse

Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

Immuno-oncolology models

HSA/hFcRn, a powerful model for your PK/PD studies

Immuno-oncolology models

Define “humanized”: two mouse models helping produce cancer immunotherapies

Humanized mouse models

A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

T-cell engager

Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Assess toxicity with ICP

Relevant preclinical models to test T-cell engagers: The case of CD28

T-cell engager

An alternative approach to immunotherapy: A bispecific agonist

Humanized PD-1 & GITR mouse

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

T-cell engager CD3

Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Assess T-cell engager in BRGSF-HIS

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Humanized PD-1/PD-L1 mouse and cell line

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Humanized HSA/hFcRn mouse

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Humanized ICP mouse and cell lines

Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

Assess T-cell engager in BRGSF-HIS

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Humanized VISTA mouse & Pharmacokinetics

An engineered humanized common light chain mouse model to develop bispecific antibodies

Humanized cLC model - Bispecific antibody development

Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized genO-hCD47/hSIRPα mouse and genO-MC38-hPD-L1-hCD47-LZ cell line

Targeting the human CD47/SIRPα axis

BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

BRGSF-HIS as model for acute implant-associated osteomyelitis

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

VISTA - safety and PK profiling

HPN328, a new T cell–activating construct for treating solid tumors

CD3ε - T-cell engager assessment

Development of a new antibody-drug conjugate against CD71, INA03, for the treatment of leukemia

TFRC for anti-cancer therapies

New CD4-specific minibodies to predict cancer treatment outcomes

CD4 for cancer treatment outcomes

A radiolabeled VISTA antibody for imaging VISTA expression

hVISTA - antibodies & PET imaging

Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

Therapeutic efficacy and pharmacokinetics

The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

Physiological relevancy in preclinical models

Uncoupling efficacy from toxicity: a case study on MEDI5752

Bispecific antibodies

Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Bispecific antibodies

No results

Other categories

Immunodeficient rodents

Explore our immunodeficient models, featuring cutting-edge strains like BRGSF mouse and SDRG rat.

Humanized mice (HIS/human immune system)

Address human-specific questions in a more relevant manner, facilitating translational research in several biomedical disciplines and approaches.

Cell lines

Our humanized & Knockout ICP cell lines can be used for in vivo tumor growth assays in syngeneic models and in vitro mechanistic studies.

Knockout and reporter models

Our off-the-shelf Knockout & reporter models are well established, validated and widely used mouse and rat lines.